Crossmark

Development of a real-world, therapeutic drug monitoring–informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections

Crossref DOI link: https://doi.org/10.1007/s11096-026-02124-0

Published Online: 2026-04-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Fusang

Zhang, Mei

Ye, Suiwen

Yan, Jianan

Li, Xuechun

Zhang, Jinyuan

Yu, Xiaoxia

Wang, Ying

Yu, Ze

Gao, Fei

Wu, Junyan
Funding

Funding for this research was provided by:

Scientific Research Fund of GuangDong Pharmaceutical Association (2023QNTJ27)

Chinese Pharmacological Society (20170711)
License Information

Text and Data Mining valid from 2026-04-17

Version of Record valid from 2026-04-17
More Information

Article History

Received: 6 January 2026

Accepted: 27 February 2026

First Online: 17 April 2026

Declarations

:

: The authors declare no competing interests.

: The study was approved by the Ethics Committee of the Sun Yat-sen Memorial Hospital, Sun Yat-sen University (No. SYSKY-2023-815-02).

Document is current

Any future updates will be listed below